(Q46199929)

20 December 2017

title

Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study (English)

1 reference

20 December 2017

ovarian hyperstimulation syndrome

main subject

1 reference

Carlos Carizza

1

1 reference

20 December 2017

Vicente Abdelmassih

2

1 reference

20 December 2017

Soraya Abdelmassih

3

1 reference

20 December 2017

Pedro Ravizzini

4

1 reference

20 December 2017

Lister Salgueiro

5

1 reference

20 December 2017

Paulo Tudech Salgueiro

6

1 reference

20 December 2017

Lin Tao Jine

7

1 reference

20 December 2017

Peter Nagy

8

1 reference

20 December 2017

Roger Abdelmassih

9

1 reference

20 December 2017

publication date

1 December 2008

1 reference

20 December 2017

Reproductive BioMedicine Online

published in

1 reference

20 December 2017

volume

17

1 reference

20 December 2017

issue

6

1 reference

20 December 2017

page(s)

751-755

1 reference

20 December 2017

Female age is an important parameter to predict treatment outcome in intracytoplasmic sperm injection.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Low dose of HCG to prevent OHSS

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Disappearance of exogenously administered human chorionic gonadotropin

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Severe OHSS: how many cases are preventable?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Low peripheral blood levels of the immunosuppressive cytokine interleukin 10 (IL-10) at the start of gonadotrophin stimulation indicates increased risk for development of ovarian hyperstimulation syndrome (OHSS).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Embryo development and pregnancies from in-vitro matured and fertilized human oocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Use of metformin for prevention of ovarian hyperstimulation syndrome: a novel approach.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Can we eliminate severe ovarian hyperstimulation syndrome? Comment I

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

In vitro maturation of human oocytes for assisted reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Distinction between early and late ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Vascular endothelial growth factor--mediator of OHSS?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Special applications of intracytoplasmic sperm injection: the influence of sperm count, motility, morphology, source and sperm antibody on the outcome of ICSI.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Maturation of human oocytes in vitro and their developmental competence.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2960401-4

7 January 2021

10.1016/S1472-6483(10)60401-4

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017